Dialysis News and Research

Latest Dialysis News and Research

JT/Torii report positive results from ferric citrate Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis.

23 Apr 2012

APS honors MCW professor with Henry Pickering Bowditch Lecture Award

High blood pressure, or hypertension, is a major problem worldwide, with the latest estimates suggesting that a billion people across the globe may have this condition. Hypertension not only takes an enormous cost on health and wellbeing, but it also exacts an expensive financial toll. Complications from this condition including kidney disease, and its resulting treatments, such as long-term dialysis and kidney transplant, are some of the costliest conditions the American health care system must contend with.

23 Apr 2012

Tengion completes FDA Pre-IND meeting for Neo-Kidney Augment preclinical program

Tengion, Inc., a leader in regenerative medicine, today announced that it recently completed a successful Pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its lead preclinical program, the Neo-Kidney Augment.

18 Apr 2012

Medgenics seeks IND approval to initiate EPODURE Biopump Phase IIb anemia study in ESRD patients

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed an Investigational New Drug application with the U.S. Food and Drug Administration to initiate a Phase IIb multi-center, 100-patient clinical trial.

18 Apr 2012

Amgen enters agreement to acquire KAI Pharmaceuticals

Amgen and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.

11 Apr 2012

DaVita introduces Kidney Smart website for patients with CKD

DaVita Inc., a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), today announced the launch of its Kidney Smart website, for anyone with questions about CKD.

10 Apr 2012

FDA selects three renal device projects for new Pathway program

A UCSF-led effort to create an implantable artificial kidney for dialysis patients has been selected as one of the first projects to undergo more timely and collaborative review at the Food and Drug Administration.

10 Apr 2012

FDA approval of OMONTYS triggers $50M milestone payment to Affymax

Affymax, Inc. today announced that it has received a $50 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize OMONTYS (peginesatide) Injection.

10 Apr 2012

Three ESRD products chosen for FDA's Innovation Pathway program

Three products for patients with end stage renal disease (ESRD) have been chosen to participate in the FDA's Innovation Pathway, an evolving system designed to help medical devices reach patients in a safe, timely and collaborative manner.

10 Apr 2012

Poor mental health can lead to heart problems and death in dialysis patients

Dialysis patients whose mental health deteriorates over time have an increased risk of developing heart problems and dying prematurely, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

6 Apr 2012

Majority of female kidney failure patients on dialysis may experience sexual problems

The vast majority of female kidney failure patients on dialysis may experience sexual problems, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Additional studies are needed to understand how sexual dysfunction affects dialysis patients' quality of life and psychological wellbeing.

6 Apr 2012

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease (CKD).

6 Apr 2012

Hypertensive dialysis patient survives 17 years on the waiting list for a new kidney

Jimmie Jones of Calumet Park, Ill., has beaten all odds to survive 17 years on the waiting list for a new kidney.

5 Apr 2012

ASN participates in ABIM Foundation's Choosing Wisely campaign

The American Society of Nephrology (ASN), the world's leading kidney organization, joins the American Board of Internal Medicine (ABIM) Foundation, eight other leading national medical specialty societies, and Consumer Reports in the new Choosing Wisely campaign that helps health care professionals and patients avoid wasteful and sometimes harmful medical interventions.

5 Apr 2012

Nine physician organizations identify specific tests or procedures that may be unnecessary

Nine leading physician specialty societies have identified specific tests or procedures that they say are commonly used but not always necessary in their respective fields. Patient advocates are calling the move a significant step toward improving the quality and safety of health care.

4 Apr 2012

Leicester Kidney Exercise Team shortlisted for BMJ award

A team of researchers from the University of Leicester, Leicester's Hospitals and the University of Loughborough are in the running for a prestigious medical award.

2 Apr 2012

DaVita thanks nearly 1,500 renal social workers during NASW

DaVita Inc., a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), today thanks its nearly 1,500 social workers for the value and care they provide to patients and their families.

29 Mar 2012

Althea provides Allena exclusive worldwide rights to broad hyperoxaluria portfolio

Allena Pharmaceuticals, Inc., and Althea Technologies today announced a licensing agreement under which Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio including product patents, regulatory information and development data related to oxalate degrading enzymes.

29 Mar 2012

FDA approves Omontys - new anemia drug for chronic kidney disease patients

The Food and Drug Administration (FDA) on Tuesday approved a new drug called Omontys (peginesatide). This is expected to oust Amgen Inc.’s from its near monopoly in the roughly $6 billion U.S. anemia treatment market.

28 Mar 2012

First Edition: March 28, 2012

Today's headlines recap yesterday's Supreme Court action related to the constitutionality of the individual mandate and set the scene for day 3 of the oral arguments, which will tackle issues of severalbility and questions about the health law's Medicaid expansion.

28 Mar 2012